Abbvie INC.
Forward trial catalysts linked to ABBV
CSA tracks 4 forward catalysts for Abbvie INC. across 4 assets, spanning Phase 3, Phase 2/3. The nearest is a readout expected Dec 2026 (month precision). Confidence across its tracked catalysts breaks down as 4 medium. Tracked indications include Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Multiple Myeloma, and 3 more.
ABBV in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Abbvie INC. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
7 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| lutikizumab | NCT06468228 catalyst | Phase 3 | Active, not recruiting | 2026-12 | Experimental | AbbVie | Hidradenitis Suppurativa |
| budigalimab | NCT06109272 catalyst | Phase 2/3 | Active, not recruiting | 2027-01 | Experimental | AbbVie | Hepatocellular Carcinoma |
| livmoniplimab | NCT06109272 catalyst | Phase 2/3 | Active, not recruiting | 2027-01 | Experimental | AbbVie | Hepatocellular Carcinoma |
| etentamig | NCT06158841 catalyst | Phase 3 | Active, not recruiting | 2027-12 | Experimental | AbbVie | Multiple Myeloma |
| budigalimab | NCT06236438 | Phase 2/3 | Recruiting | 2031-10 | Experimental | AbbVie | Non-Small Cell Lung Cancer |
| livmoniplimab | NCT06236438 | Phase 2/3 | Recruiting | 2031-10 | Experimental | AbbVie | Non-Small Cell Lung Cancer |
| etentamig | NCT07728188 | Phase 3 | Not yet recruiting | 2033-02 | Experimental | AbbVie | Relapsed or Refractory Multiple Myeloma |
| etentamig | NCT07793422 | Phase 3 | Not yet recruiting | 2034-12 | Experimental | AbbVie | Amyloid Light Chain (AL) Amyloidosis |
| etentamig | NCT07095452 | Phase 2/3 | Recruiting | 2040-09 | Experimental | AbbVie | Multiple Myeloma |
Every trial the CSA sample links to ABBV's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →